A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis

Journal of Pharmaceutical and Biomedical Analysis

Volumn 114, Issue , 2015, Pages 82-87

  Mano, Yuji ^a   Kusano, Kazutomi ^a  

^a EISAI CO LTD   (Japan)

Author keywords

Human serum; LC MS MS; Lenvatinib; Protein binding; Validation

Indexed keywords

ER 227326; LENVATINIB; PHOSPHATE BUFFERED SALINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ACETIC ACID DERIVATIVE; AMMONIUM ACETATE; CARBANILAMIDE DERIVATIVE; CELLULOSE; ION; PROTEIN BINDING; QUINOLINE DERIVATIVE; SOLVENT;

ACCURACY; ARTICLE; CHEMICAL STRUCTURE; DRUG STABILITY; EQUILIBRIUM DIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; PLASMA PROTEIN BINDING; POSITIVE ION ELECTROSPRAY; PRIORITY JOURNAL; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; UNBOUND FRACTION; BLOOD; CALIBRATION; CHEMISTRY; HUMAN; LIMIT OF DETECTION; PH; PROCEDURES; QUALITY CONTROL; VALIDATION STUDY;

ACETATES; CALIBRATION; CELLULOSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROGEN-ION CONCENTRATION; IONS; LIMIT OF DETECTION; PHENYLUREA COMPOUNDS; PROTEIN BINDING; QUALITY CONTROL; QUINOLINES; REPRODUCIBILITY OF RESULTS; SOLVENTS; TANDEM MASS SPECTROMETRY;

EID: 84930210327     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2015.05.008     Document Type: Article

References (10)

1. Matsui J., Yamamoto Y., Funahashi Y., Tsuruoka A., Watanabe T., Wakabayashi T., Uenaka T., Asada M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 2008, 122:664-671.
2. Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin. Cancer Res. 2008, 14:5459-5465.
3. Okamoto K., Kodama K., Takase K., Sugi N.H., Yamamoto Y., Iwata M., Tsuruoka A. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013, 340:97-103.
4. Boss D.S., Glen H., Beijnen J.H., Keesen M., Morrison R., Tait B., Copalu W., Mazur A., Wanders J., O'Brien J.P., Schellens J.H., Evans T.R. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br. J. Cancer 2012, 106:1598-1604.
5. Yamada K., Yamamoto N., Yamada Y., Nokihara H., Fujiwara Y., Hirata T., Koizumi F., Nishio K., Koyama N., Tamura T. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17:2528-2537.
6. Dubbelman A.C., Rosing H., Thijssen B., Gebretensae A., Lucas L., Chen H., Shumaker R., Schellens J.H., Beijnen J.H. Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2012, 888:25-34.
7. Mathieu O., Hillaire-Buys D., Dadure C., Barnay F., Mathieu-Daudé J.C., Bressolle F. Liquid chromatography-electrospray mass spectrometry determination of free and total concentrations of ropivacaine in human plasma. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2006, 831:91-98.
8. Sillén H., Cook M., Davis P. Determination of unbound ticagrelor and its active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis and LC-MS/MS. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2011, 879:2315-2322.
9. European Medicines Agency Guideline on Bioanalytical Method Validation 2011, Committee for Medicinal Products for Human Use, Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
10. US Food and Drug Administration Guidance for Industry: Bioanalytical Method Validation 2001, Available online at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.